Year End Trading Update

For Stock Exchange release at 7.00 a.m. Thursday 6 October 2011

Trading Statement

The Company announces its trading update for the year ended 30 September 2011.

Full year Group sales volume amounted to 2,860 tonnes, an increase of 13% over the previous year (2,535 tonnes).

Full year revenue for Invibio®, our biomaterial solutions business, was £49.7m, an increase of 12% over the previous year (£44.2m) despite challenging market conditions.

Overall, we expect Group profits for 2011 to be in line with market expectations.

Initial trading for October indicates that the Group continues to perform well. However, we remain vigilant of the uncertain macroeconomic indicators and the potential impact on our customers and markets.

The Group remains in an excellent financial position with a healthy balance sheet and strong cash generation. We believe we are well placed to pursue future growth and investment opportunities across both our VPS and Invibio businesses.

Victrex will announce its results for the year ended 30 September 2011 on Tuesday 6 December 2011.

Victrex will host a conference call at 8am on Thursday 6 October for analysts. If you would like more details, please ring Ian Payne at MHP on 0203 128 8755 or email him on [email protected].

Enquiries

Victrex plc 01253 898067

Anita Frew, Chairman

David Hummel, Chief Executive

Steve Barrow, Finance Director

MHP Communications 0203 128 8100

Nick Denton

Barnaby Fry

Ian Payne

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK™ polymer, a high performance, easy to process thermoplastic.

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions business ('VPS') focuses on our transport, industrial and electronics markets and our Invibio Biomaterial Solutions business ('Invibio') focuses on providing specialist solutions for medical device manufacturers.